Beta Bionics (Nasdaq:BBNX) shares rose after hours today on raised 2025 guidance and second-quarter results that beat the consensus forecast.
The company increased its 2025 guidance for revenues between $88 million and $93 million. It previously projected between $82 million and $87 million.
Shares of BBNX ticked up nearly 5% to $15.35 apiece in post-market trading today.
The Irvine, California-based automated insulin delivery technology developer reported losses of $17 million for the quarter. That equals 39¢ per share on sales of $23.2 million for the three months ended June 30, 2025.
Beta Bionics recorded a 17.1% bottom-line slide on a sales increase of 54.4%. Earnings per share landed 8¢ ahead of expectations on Wall Street. Sales also topped the forecasts as experts projected $19.7 million in revenue.
The rollout of the iLet bionic pancreas system continues to support growth. The company reported 4,934 new patient starts, up 57% compared to the same period a year ago. Nearly three-quarters (71%) of those new starts came from multiple daily injections.
Recent highlights include the unveiling of the “Mint” patch pump in development, plus data on the use of the flagship iLet system in a “fully closed-loop” manner. The company also has effective formulary agreements in place with all major pharmacy benefit managers (PBMs) in the U.S.
Beta Bionics also completed dosing this month for its glucagon pharmacokinetic (PK)-pharmacodynamic (PD) bridging trial in Canada. It plans for the trial to enable it to bridge previous bihormonal clinical data to its glucagon candidate developed by Xeris. They hope to bring the bihormonal configuration to the iLet system.
The company expects full results from the bridging trial this year, informing the go-forward development strategy from there.
